Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00730
|
|||||
Drug Name |
Maraviroc
|
|||||
Synonyms |
376348-65-1; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; CHEBI:63608; CHEMBL1201187; CHEMBL256907; Celsentri; Celsentri (TN); Celsentri(TM); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; MD6P741W8A; MVC; Maraviroc [USAN]; PRO 140 & Maraviroc; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; Selzentry; Selzentry (TN); Selzentry(TM); UK 427857; UK-427,857; UK-427,857 maraviroc (MVC); UK-427857; UNII-MD6P741W8A; [3H]maraviroc
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Human immunodeficiency virus infection [ICD11: 1C62.Z] | Approved | [1] | |||
Therapeutic Class |
Anti-HIV Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C29H41F2N5O
|
|||||
Canonical SMILES |
CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C
|
|||||
InChI |
InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1
|
|||||
InChIKey |
GSNHKUDZZFZSJB-HLMSNRGBSA-N
|
|||||
CAS Number |
CAS 376348-65-1
|
|||||
Pharmaceutical Properties | Molecular Weight | 513.7 | Topological Polar Surface Area | 63 | ||
Heavy Atom Count | 37 | Rotatable Bond Count | 8 | |||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 6 | |||
XLogP |
5.1
|
|||||
PubChem CID | ||||||
ChEBI ID |
CHEBI:63608
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
References | ||||||
1 | Maraviroc was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.